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medical outcomes, reducing costs, and 
enhancing patients ’ HRQOL needs addi-
tional emphasis and attention. 
 Lessons from the care of ESRD patients 
in this regard may be helpful. A high inci-
dence of clinical depression in ESRD 
patients is well documented. 1,5 Various 
treatment options have now been shown 
to be helpful in reducing depressive symp-
toms. 1,5 Th ese options include both phar-
macological and non-pharmacological 
therapies, including cognitive-behavioral 
therapy, exercise, and modifi cations in the 
dialysis treatment regimen. 1,5 It has been 
proposed that ESRD patients routinely be 
screened with validated questionnaires 
inquiring about depressive symptoms and 
that those patients with scores above 
 certain predetermined values have direct 
interviews to screen for clinical depres-
sion. 1,5 Appropriate treatment options can 
then be discussed with the patient. Could 
a similar algorithm be developed for CKD 
patients? 
 Fischer  et al. 8 emphasize that it is the 
fi nancially disadvantaged who need the 
most support — perhaps sending a mes-
sage to health-care policy makers in the 
United States about the need for health-
care reform. It is this population (the 
unemployed and low-wage earners) who 
oft en lack proper health insurance and 
thus are deprived of the health care that 
they so need. We must ask ourselves to 
what extent the high incidence of ESRD 
in these groups of patients refl ects their 
limited access to care rather than a genetic 
predisposition. 
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 Th erapeutic interventions are generally 
based on an evaluation of clinical data, 
diagnostic information, and availability 
of the therapy and ancillary resources. 
Th ere is an increasing appreciation that 
the timing of therapy is an important 
determinant of outcomes, particularly if 
the intervention targets a specifi c mech-
anism or pathway involved in the disease 
process. For instance, management of 
acute chest pain syndromes and stroke 
emphasizes early interventions within a 
few hours from the event. Th erapy is tar-
geted to mitigate the eff ects of platelet 
adherence and activation, which have 
been implicated in the development of 
the ischemic injury. Th ese strategies have 
dramatically altered outcomes and 
resulted in improved survival and have 
further demonstrated the time-depend-
ent relationship of the benefi t. On the 
basis of these observations, it is apparent 
that interventions based on  ‘ windows of 
opportunity ’ coupled with targeted ther-
apy are an important construct for man-
aging diseases. However, in kidney 
disease, these approaches are applied 
only in a limited fashion. Unlike myocar-
dial infarction and stroke, kidney disease 
is largely asymptomatic, and kidney 
injury may be discovered only late in the 
course. Consequently, precise timing has 
usually not been a major focus, particu-
larly in chronic kidney disease (CKD), 
since the progression generally occurs 
over weeks and months. Additionally, 
although several targets have been iden-
tifi ed, few are actually used — for exam-
ple, angiotensin-converting enzyme 
inhibitors for slowing progression. Simi-
larly, in acute kidney injury (AKI), a 
sense of therapeutic nihilism has pre-
vailed, with no clear therapeutic options 
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other than dialysis, which is considered 
only for severe renal failure. 
 Th ese paradigms are now changing. 
Progress in establishing standardized 
diagnostic and staging criteria for AKI 1 
has resulted in accumulating evidence 
that small decrements in renal function 
contribute to increased mortality and 
other adverse outcomes. Concurrent 
progress in identifying biomarkers of AKI 
has prompted a resurgence of interest in 
earlier diagnosis of AKI and, potentially, 
earlier interventions. Th e current diagno-
sis and staging of AKI is based on evi-
dence of decreased glomerular fi ltration 
rate with measurable changes in serum 
creatinine and urine output ( Figure 1 ). 
However, in most situations these func-
tional changes are preceded by kidney 
injury, suggesting that targeted interven-
tions need to start earlier than changes in 
serum creatinine. However, recognizing 
when injury has started, whether it is 
progressing, and which mechanisms are 
involved are the key challenges to identi-
fying the optimal time for intervention. 
Several AKI biomarkers are now being 
evaluated to provide this information, 
and it is likely that multi-marker combi-
nations may be needed to inform this 
process. 2 As we await further advances in 
this arena, the EARLYARF study by 
Endre  et al. 3 (this issue) provides 
a glimpse of the challenges and opportu-
nities that lie ahead. 
 On the basis of promising preclinical 
data demonstrating that erythropoietin 
(EPO) could prevent development of 
AKI, these investigators performed a 
double-blind placebo-controlled trial to 
study whether early treatment (within 
6  hours of injury) with high-dose EPO 
(up to 50,000 U) could prevent the devel-
opment of AKI in intensive care unit 
(ICU) patients. As a guide for choosing 
the patients for treatment, they measured 
urinary levels of two biomarkers, the 
proximal tubular brush border enzymes 
  -glutamyltranspeptidase and alkaline 
phosphatase. Randomization to either 
placebo or two doses of EPO was trig-
gered by an increase in the biomarker 
concentration product to levels above the 
threshold previously established in a prior 
study. Of 529 patients, 162 were rand-
omized. Although early intervention with 
high-dose EPO was safe, it did not alter 
outcome. Th e unique trial design, com-
bining an observational and intervention 
arm, and the fi ndings are instructive for 
the design and conduct of future studies 
in this fi eld. 
 Th e use of biomarkers to identify and 
triage patients for an intervention empha-
sizes the importance of several key issues. 
Although the elevation of   -glutamyl-
transpeptidase and alkaline phosphatase 
identifi ed patients with worse outcomes, 
the tests were poor in predicting AKI, with 
receiver operating characteristic curves of 
0.54. Th is discrepancy represents some of 
the practical concerns in biomarker devel-
opment for AKI. As shown in  Figure 1 , 
biomarkers can detect kidney injury 
earlier in the course, identify the underly-
ing mechanism, and identify potential 
targets. However, to pinpoint the  ‘ window 
of opportunity, ’ biomarkers need to have 
a high sensitivity and specifi city and to be 
measured frequently enough. AKI biomar-
kers diff er on the basis of how they enter 
the urine, either through fi ltration, upreg-
ulation, and secretion or through leakage 
from damage of a constitutive marker. 4 
The time sequence and magnitude of 
biomarker elevations are unique and prob-
ably depend on the nature and severity of 
injury. Transient reductions in glomerular 
fi ltration rate related to renal compensa-
tory mechanisms and  ‘ prerenal ’ factors 
add another layer of complexity. Given the 
heterogeneity of underlying patient char-
acteristics, severity of illness, and potential 
reasons for decreased renal function in 
ICU patients, biomarker elevations may 
not track changes in serum creatinine. 
Although urinary indices were evaluated 
in the EARLYARF study, they did not 
improve biomarker discrimination. Spe-
cifi c mechanisms for adjudicating biomar-
ker elevations in the absence of clinical 
events need to be developed. A prerequi-
site will be to develop consensus for clini-
cal end points, including clear defi nitions 
of what constitutes a prerenal state. 5 Th e 
timing of biomarker measurements was 
dictated by protocol, with assessments at 
ICU admission, at 12 and 24  hours, and 
then once daily. Th is window may not be 
suffi  cient to capture the natural biology of 
the disorder; however, it refl ects the prac-
ticality of collecting samples in an ICU 
environment. 
 Designating an appropriate end point for 
clinical trials in AKI continues to be a vex-
ing problem. In the EARLYARF study, the 
primary outcome was the increase in the 
relative average value of creatinine (RAVC) 
from baseline over 4 – 7 days. 6 However, for 
the vast majority of patients, no creatinine 
measurement from before the ICU admis-
sion was available, and consequently AKI 
was based on  post hoc analysis using diff er-
ent criteria, including the lowest initial 
creatinine value on entry to the ICU, the 
last ICU value, or the  minimum value at 
 Figure 1  |  Opportunities for timed and targeted therapy in AKI. Surveillance could be initiated 
for high-risk individuals on the basis of clinical and biomarker criteria. Sequential assessment 
of biomarkers may permit identification of a window of opportunity in which kidney injury has 
been initiated but has not progressed to renal functional change. The duration of this window 
is inherently dependent on the type and site of injury and the nature and specificity of the 
biomarkers to determine the targets for intervention. Progression of kidney injury would be 
determined by development of functional changes staged on the basis of the severity of kidney 
injury. Biomarkers could further define progression, determine need for additional interventions, 
and predict prognosis. GFR, glomerular filtration rate. 
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follow-up to 365 days. Th ese varying crite-
ria can clearly influence the diagnostic 
accuracy. For instance, the last ICU value 
and the minimum value at 365 days both 
occur aft er the AKI event and do not refl ect 
the patient ’ s state of heath before the ICU 
admission. Any value during or aft er the 
illness is likely infl uenced not only by the 
level of kidney function but also by the 
body mass, volume of distribution, and 
diet at that time point. It has been suggested 
that a baseline creatinine value be back-cal-
culated with the Modifi cation of Diet in 
Renal Disease formula by input of an iden-
tical glomerular fi ltration rate (typically 
75  ml / min per 1.73  m 2 ). 7 Although this 
method takes into account an individual ’ s 
age, sex, and ethnicity, it overestimates 
renal function particularly in patients 
with CKD. 8 Th e course of CKD is diff er-
ent from that of new-onset AKI, and this 
supports the need to ascertain renal func-
tion prior to AKI. 9 Given these con-
straints, what should be considered as the 
baseline creatinine value for AKI studies? 
Creatinine values prior to the develop-
ment of AKI should inform the clinician 
whether a patient has preexisting kidney 
disease, has an ongoing episode of AKI, or 
has normal renal function. Since CKD 
requires a minimum interval of 90 days 
for its diagnosis, creatinine values more 
than 90 days from the event represent the 
 ‘ baseline ’ renal function and can charac-
terize a patient ’ s CKD status. Within the 
90-day interval it is more diffi  cult to ascer-
tain the implication of an elevated creati-
nine; however, these values could serve as 
a reference point against which further 
changes in creatinine could be assessed to 
diagnose or stage AKI on the basis of the 
Acute Kidney Injury Network interval 
(48  hours) or the RIFLE interval (7 days). 
I would suggest that distinguishing a 
 ‘ baseline ’ creatinine value to inform a per-
son ’ s CKD status and a  ‘ reference ’ value to 
defi ne a starting point for AKI diagnosis 
and staging would permit clearer com-
parisons among future studies. A key issue 
is, in the presence of several measure-
ments, which one should serve as the 
reference point. Certainly, further discus-
sion of these matters is required for 
future studies. 
 Prior therapeutic interventions in AKI 
have included atrial natriuretic peptides, 
growth factors, diuretics, dopamine, and 
fenoldopam but have not been success-
ful. In the EARLYARF trial, preclinical 
data strongly suggested a rationale for 
using EPO as a renoprotective agent 
early in AKI. 10 However, as has oft en 
been the case in AKI for a variety of rea-
sons, these preclinical results were not 
borne out in clinical trials. Whether the 
timing was early enough is a considera-
tion. At randomization, over 35 % of 
patients had already met criteria for AKI 
despite the effi  ciency of triaging and ini-
tiating EPO within 3.5  hours of the pos-
itive biomarker test. In these patients 
with AKI, reduction of further progres-
sion of the AKI stage and improvement 
of recovery would be the anticipated end 
points rather than development of AKI. 
Unfortunately, the study was not pow-
ered to detect differences in the sub-
groups. Results from other recent trials 
have provided a cautionary note for use 
of high doses of EPO 11 and raise the con-
cern that the lack of benefi t could repre-
sent direct eff ects of EPO. Th ere was no 
diff erence in the incidence of EPO-spe-
cifi c adverse events or in the primary 
outcome between placebo and treatment 
groups. However, in the subgroup of 
patients who did not have AKI at rand-
omization, the RAVC was worse with 
EPO, although the study was not pow-
ered to detect these events. Finally, the 
decision to randomize was based solely 
on the threshold value of the biomarkers 
without consideration of additional clin-
ical factors that would determine the risk 
of developing AKI. Combining clinical 
risk and biomarker assessment would 
probably improve the recognition of 
patients most likely to benefi t. Certainly 
the availability of point-of-care tests for 
AKI biomarkers may permit more fre-
quent and rapid estimation of biomark-
ers for future studies. 12 
 Endre  et al. 3 are to be congratulated for 
their diligence and eff ort in designing and 
conducting this study and providing 
unique insights for future research. Further 
work is clearly needed to inform the time 
course and performance of AKI  biomarkers 
in various situations, to identify the path-
ways involved, to defi ne clinical end points, 
including prerenal states, and to improve 
adjudication of biomarker data with 
respect to functional changes. It is clear 
that improving outcomes in AKI will take 
a concerted eff ort to equip the clinician 
with the best tools for risk assessment, sur-
veillance, and early targeted therapy. Th e 
window of opportunity is now wide open 
for research in the fi eld and hopefully will 
lead to new knowledge to improve patient 
care in the coming years. 
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